Dyslipidemia – Epidemiology Insights and Forecast Report – 2020 To 2040
Dyslipidemia
Epidemiology Insights
Thelansis’s “Dyslipidemia
Epidemiology Insights and Forecast Report – 2020 To 2040″ provides an
analysis of disease burden, characterized by disease definition, prevalence,
incidence, diagnosed cases, severity, comorbidities, and clinical
manifestations. Potential patient flow dynamics in disease burden are driven by
shifts in demographic indicators and their correlation with age and gender
distribution over time. Changes in the reported cases and long-term survival of
patients may depend on diet, lifestyle, comorbid conditions, and the
availability of interventions or therapies.
Dyslipidemia Overview
Dyslipidemia is a metabolic disorder
characterized by persistent imbalances in blood lipid levels, specifically
involving elevated low-density lipoprotein (LDL) cholesterol, increased
triglycerides, or pathologically low high-density lipoprotein (HDL) cholesterol.
This condition serves as a primary driver of atherosclerosis, where lipid
deposits and fibrous plaques narrow the arterial walls, progressively
restricting blood flow to vital organs. While often asymptomatic in its early
stages, the underlying biochemical dysfunction—whether triggered by genetic
predispositions like Familial Hypercholesterolemia or lifestyle factors such as
sedentary habits and poor nutrition—significantly heightens the risk of acute
cardiovascular events, including myocardial infarction and stroke. Effective
management typically requires a multifaceted clinical approach that combines
lipid-lowering pharmacotherapies, such as statins or PCSK9 inhibitors, with
aggressive dietary modifications to restore lipid homeostasis and protect
vascular integrity.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Deliverables
format and updates*:
- Access to an interactive epidemiology
platform with downloadable Excel and PPT files.
- Global findings
- G8 findings
- Regional
findings
- Country-specific
findings
- Others*: regular updates,
customizations, epidemiologist support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the content. Countries, subpopulations, and years of forecast can be
customized as per client requirements.
Key business
questions answered:
- 20-year historical and forecast data
(2020–2040)
- Disease definition based on globally
accepted and latest criteria (e.g., ICD-10 codes)
- Granular patient population coverage
by year and geography
- Detailed segmentation by age, gender,
subpopulations, comorbidities, line of therapies, etc.
- Patient funnels
- Country comparisons
- Relevant clinical variables (e.g.,
staging/classification/severity)
Insights
driven by robust research and estimates:
- Published literature (e.g.,
peer-reviewed journal articles, registries, national surveys)
- Primary market research with KOLs
- RWD analysis using claims and EHR
datasets
- Proprietary mathematical models
(e.g., incidence-survival model;
incidence- recurrence/progression-survival model)
Read more: Dyslipidemia – Epidemiology Insights and Forecast
Report – 2020 To 2040
Comments
Post a Comment